MDGL
MADRIGAL PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$399.63
+0.84%Year over year
Reported trailing growth
- Revenue
- +92.8%
- EBITDA
- +54.9%
- EBIT
- +50.4%
- EPS
- +54.6%
- Free cash flow
- -4.3%
- Operating cash flow
- +2.2%
Forward estimates
Based on analyst estimates
- Revenue
- +37.3%
- EBITDA
- +189.7%
- EPS
- +132.6%
Three-year CAGR
- Revenue
- +432.1%
- EBITDA
- +41.2%
- EBIT
- +39.7%
- Net income
- +38.1%
- EPS
- +41.3%
- Free cash flow
- +58.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026